Effect of antihormones on endometrial receptors and protein secretion
Review
OA: closed
CC0
AI-generated summary
Tamoxifen and RU 486 differentially affect endometrial development, receptor levels, and protein secretion, with RU 486 acting as a pure antagonist and tamoxifen exhibiting mixed agonist/antagonist activity.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The antiestrogen tamoxifen and the antiprogestin RU 486 both interact with respective hormones at the receptor level, RU 486 as a pure antagonist which inhibits endometrial development, the downregulation of estrogen and progesterone receptors and the production of endometrial protein, such as PP14, during the secretory phase of the menstrual cycle. Tamoxifen, on the other hand, has both agonistic and antagonistic action.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
References (9)
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis via openalex
- The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium via openalex
- W2130196753 via openalex
- W2272743743 via openalex
- W2295027276 via openalex
- W2411884256 via openalex
- W2416315955 via openalex
- W4290310367 via openalex
- W1917105397 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:59:31.578486+00:00
- unpaywall
- last seen: 2026-10-10T06:25:47.132674+00:00
License: CC0
· commercial use OK